Market Overview

Morgan Stanley Remains Confident In CIGNA Following Management Visit

Share:
Related CI
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Economic Data
Valuation Dashboard: Healthcare - Update (Seeking Alpha)

In a report published Wednesday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating and $99.00 price target on CIGNA (NYSE: CI).

In the report, Morgan Stanley noted, “Expect continued improvement in Medicare. Cigna may not see the full benefit of some of the triage activities it implemented to improve the Medicare business in 2H13 until 2H14. The measures included identifying underperforming facilities, renegotiating reimbursement rates, and modifying networks where necessary. Recall, the company has not incorporated any improvement in Medicare in its FY14 outlook. In addition, Cigna anticipates an improvement in Medicare margins in FY15 as it continues to enhance networks and products.”

CIGNA closed on Tuesday at $89.12.

Latest Ratings for CI

DateFirmActionFromTo
Sep 2016Evercore ISI GroupInitiates Coverage onHold
Aug 2016CitigroupMaintainsBuy
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for CI
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CI)

View Comments and Join the Discussion!